Related Experiment Video
Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Bevacizumab (Avastin)]
1Dept. of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital.
Abstract:
Vascular endothelial growth factor(VEGF)is a key mediator in angiogenesis, an essential step in tumor growth and metastasis. Elevated levels of VEGF observed in solid tumors are correlated with worse clinical outcomes. Research has therefore focused on developing agents that target VEGF to inhibit tumor growth. Bevacizumab(Avastin), a recombinant humanized monoclonal antibody targeting VEGF. Bevacizumab with conventional chemotherapy has shown antitumor activity in several cancer types with acceptable toxicity. In April 2007, the Japanese Ministry of Health, Labour and Welfare approved bevacizumab for patients with unresectable colorectal cancer.
Insights
Vascular endothelial growth factor (VEGF) drives tumor growth and spread. Bevacizumab, an antibody targeting VEGF, combined with chemotherapy, shows antitumor activity and was approved for colorectal cancer in Japan.
Area of Science:
- Oncology
- Molecular Biology
- Angiogenesis Research
Context:
- Vascular endothelial growth factor (VEGF) is crucial for tumor angiogenesis, growth, and metastasis.
- Elevated VEGF levels in solid tumors correlate with poor clinical outcomes.
- Targeting VEGF is a key strategy in cancer therapy development.
Purpose:
- To investigate the efficacy and safety of bevacizumab, a monoclonal antibody targeting VEGF.
- To evaluate bevacizumab in combination with conventional chemotherapy for cancer treatment.
Summary:
- Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF.
- Clinical studies demonstrate antitumor activity when bevacizumab is administered with chemotherapy.
- The treatment exhibits acceptable toxicity profiles in various cancer types.
Impact:
- Bevacizumab offers a targeted approach to inhibit tumor angiogenesis and progression.
- Its approval for unresectable colorectal cancer in Japan (April 2007) signifies clinical utility.
- This highlights the therapeutic potential of anti-VEGF agents in oncology.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

